110393 ⎘
Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV Viruses as such, e.g. new isolates, mutants or their genomic sequences
Novel HIV-1 Variants And Their Methods Of Use In An Animal Challenge Model
#2USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
#3SINDBIS CONTROL VIRUS
#4Methods and compositions for generating a deletion library and for identifying a defective interfering particle (DIP)
#5Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
#6Recombinant HIV compositions and uses thereof in animal models
#7Method for detecting HIV-1 co-receptor tropism
#8Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
#9Methods for discriminating between HIV-1 and lentiviral vectors
#10ENGINEERED HUMAN HOOKWORMS AS A NOVEL BIODELIVERY SYSTEM FOR VACCINES AND BIOLOGICALS
#11Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
#12METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
#13SINDBIS CONTROL VIRUS
#14Methods for discriminating between HIV-1 and lentiviral vectors
#15Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
#16Compositions and Methods for Treating an Immunodeficiency Virus Infection
#17Viral inhibitory nucleotide sequences and vaccines
#18Live, attenuated vaccines and methods of making and using
#19Method for producing enveloped viruses
#20COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION
#21Immunogenic compositions comprising silicified virus and methods of use
#22Method for designing a drug regime for HIV-infected patients
#23Monoclonal antibodies directed against a novel pathogenic west African human immunodeficiency virus type 2 (HIV-2) group F isolate
#24Cells and methodology to generate non-segmented negative-strand RNA viruses
#25DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS
#26Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate
#27Human immunodeficiency virus and uses thereof
#28NOVEL HIV-BASED RECOMBINANT VIRAL CLONES AND USE THEREOF IN ANALYTICAL METHODS
#29Recoding method that removes inhibitory sequences and improves HIV gene expression
#30Non-M, non-O HIV-1 strains, fragments and uses
#31Cells and methodology to generate non-segmented negative-strand RNA viruses
#32Method for designing a drug regime for HIV-infected patients
#33Modified human immunodeficiency virus clade C envelope polypeptides obtained from a zambian isolate
#34Cell line for producing a non-retroviral vector
#35Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens
#36Retrovirus from the HIV group and its use
#37Non-M, non-O HIV-1 strains, fragments and uses
#38Retroviral vectors expressing exogenous gene or exogenous nucleic acid sequences
#39Retrovirus from the HIV group and its use
#40Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
#41Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1
#42Non-pathogenic strains of HIV-1
#43CD4-independent HIV envelope proteins as vaccines and therapeutics
#44Ancestral and COT viral sequences, proteins and immunogenic compositions
#45Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
#46Retrovirus from the HIV group and its use